首页> 外文期刊>Cell biochemistry and biophysics >Therapeutic Path to Double Knockout: Investigating the Selective Dual-Inhibitory Mechanisms of Adenosine Receptors A1 and A2 by a Novel Methoxy-Substituted Benzofuran Derivative in the Treatment of Parkinson's Disease
【24h】

Therapeutic Path to Double Knockout: Investigating the Selective Dual-Inhibitory Mechanisms of Adenosine Receptors A1 and A2 by a Novel Methoxy-Substituted Benzofuran Derivative in the Treatment of Parkinson's Disease

机译:双重敲除的治疗途径:通过新的甲氧基取代的苯并呋喃衍生物研究腺苷受体A1和A2的选择性双抑制机制治疗帕金森病

获取原文
获取原文并翻译 | 示例
           

摘要

The dual inhibition of adenosine receptors A1 (A(1) AR) and A2 (A(2A) AR) has been considered as an efficient strategy in the treatment of Parkinson's disease (PD). This led to the recent development of a series of methoxy-substituted benzofuran derivatives among which compound 3j exhibited dual-inhibitory potencies in the micromolar range. Therefore, in this study, we seek to resolve the mechanisms by which this novel compound elicits its selective dual targeting against A(1) AR and A(2A) AR. Unique to the binding of 3j in both proteins, from our findings, is the ring-ring interaction elicited by (A1)Phe275 (-> (A2)Phe170) with the benzofuran ring of the compound. As observed, this pi-stacking interaction contributes notably to the stability of 3j at the active sites of A(1) and A(2A) AR. Besides, conserved active site residues in the proteins such as (A1)Ala170 (-> (A2)Ala65), (A1)Ile173 (-> (A2)Ile68), (A1)Val191 (-> (A2)Val86), (A1)Leu192 (-> (A2)Leu87), (A1)Ala195 (-> (A2)Ala90), (A1)Met284 (-> (A2)Met179), (A1)Tyr375 (-> (A2)Tyr369), (A1)Ile378 (-> (A2)Ile372), and (A1)His382 (-> (A2)His376) were commonly involved with other ring substituents which further complement the dual binding and stability of 3j. This reflects a similar interaction mechanism that involved aromatic (pi) interactions. Consequentially, vdW energies contributed immensely to the dual binding of the compound, which culminated in high Delta G(binds) that were homogenous in both proteins. Furthermore, 3j commonly disrupted the stable and compact conformation of A(1) and A(2A) AR, coupled with their active sites where C alpha deviations were relatively high. Ligand mobility analysis also revealed that both compounds exhibited a similar motion pattern at the active site of the proteins relative to their optimal dual binding. We believe that findings from this study with significantly aid the structure-based design of highly selective dual-inhibitors of A(1) and A(2A) AR.
机译:腺苷受体A1(A(1)AR)和A2(A(2A)AR)的双重抑制被认为是治疗帕金森病(PD)的有效策略。这导致了最近一系列甲氧基取代苯并呋喃衍生物的开发,其中化合物3j在微摩尔范围内表现出双重抑制效力。因此,在本研究中,我们试图解决这种新化合物诱导其针对(1)AR和(2A)AR的选择性双重靶向的机制。根据我们的发现,(A1)Phe275(->(A2)Phe170)与化合物的苯并呋喃环诱导的环-环相互作用是两种蛋白质中3j结合的独特之处。正如所观察到的,这种pi堆积相互作用显著地有助于3j在A(1)和A(2A)AR活性位点上的稳定性。此外,蛋白质中保守的活性位点残基,如(A1)Ala170(->(A2)Ala65),(A1)Ile173(->(A2)Ile68),(A1)Val191(->(A2)Val86),(A1)Leu192(->(A2)Leu87),(A1)Ala195(->(A2)Ala90),(A1)Met284(->(A2)Met179),(A1)Tyr375(->(A2)Tyr369),(A1)Ile378(->(A2)Ile372)和(A1)His382(->(A2)His376)通常与其他环取代基有关,这些取代基进一步补充了3j的双重结合和稳定性。这反映了一种类似的相互作用机制,涉及芳香族(pi)相互作用。因此,vdW能量极大地促进了该化合物的双重结合,最终在两种蛋白质中均为同质的高δG(结合)。此外,3j通常会破坏A(1)和A(2A)AR稳定紧凑的构象,以及它们的活性位点,其中Cα偏差相对较高。配体迁移率分析还显示,这两种化合物在蛋白质的活性位点相对于其最佳双结合表现出相似的运动模式。我们相信,这项研究的发现大大有助于基于结构的高选择性A(1)和A(2A)AR双重抑制剂的设计。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号